According to Bloomberg, the vaccine that Oxford University is working on with AstraZeneca Plc (AZN.UK) showed promising results in the initial phase of human testing. According to the researchers involved in the study, the vaccine was expected to increase the levels of antibodies and lymphocytes that fight the coronavirus. The results were published today in the medical journal The Lancet. While the above observations do not yet mean that the vaccine will be fully effective, it is a key step in the initial testing phase.
AstraZeneca Plc (AZN.UK) shares are highly volatile today. Successful reports on a potential vaccine inflame investors' hopes once again. Initially price soared by nearly 10%, however after a while the price started to decline and is approaching the support level at 90,510. In case of further downward movements, investors should focus on 81.310, where we have seen previous price reactions. It is worth bearing in mind that any reports related to the AstraZeneca vaccine may greatly affect the company's stock price. Source: xStation5
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile appThis content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
